Clicky

CareDx, Inc.(CDNA)

Description: CareDx, Inc. develops, markets, and delivers a diagnostic surveillance solution for heart transplant recipients to help clinicians make personalized treatment decisions throughout a transplant patient's lifetime. It provides AlloMap, a noninvasive blood test used to aid in the identification of heart transplant recipients with stable allograft function who have a low probability of moderate/severe acute cellular rejection at the time of testing in conjunction with standard clinical assessment. The company also offers AlloMap Molecular Expression Testing, an in vitro diagnostic multivariate index assay test service performed in a single laboratory assessing the gene expression profile of RNA isolated from peripheral blood mononuclear cells. It markets and sells its products through distribution partners in the United States, Canada, and Europe. CareDx, Inc. was formerly known as XDx, Inc. and changed its name to CareDx, Inc. in April 2014. The company was incorporated in 1998 and is based in Brisbane, California.


Keywords: Medicine Clinical Medicine In Vitro Gene Expression Blood Test Transplantation Medicine Organ Transplantation Transplant Rejection Heart Transplant Heart Transplantation

Home Page: www.caredx.com

CDNA Technical Analysis

1 Tower Place
South San Francisco, CA 94080
United States
Phone: 415 287 2300


Officers

Name Title
Dr. Reginald Seeto Pres, CEO & Director
Dr. Peter Maag Ph.D. Exec. Director
Ms. Sasha King M.B.A. Exec. Officer
Mr. Marcel Konrad Sr. VP of Fin. & Accounting
Mr. Alexander L. Johnson Pres of Patient and Testing Services
Mr. Abhishek Jain CFO, VP, Corp. Controller, Principal Financial Officer & Principal Accounting Officer
Ms. Marica Grskovic Ph.D. Chief Operating Officer
Mr. Abraham Ronai Esq. Gen. Counsel, Chief Admin. & Legal Officer and Sec.
Mr. Ian Cooney VP of Investor Relations
Dr. Mickey Y. Kim M.D. Sr. VP of Corp. Devel. & Head of Global Product

Exchange: NASDAQ

Country: US

Currency: US Dollar ($)

Forward PE: 0
Trailing PE: 0
Price-to-Book MRQ: 1.5754
Price-to-Sales TTM: 2.0188
IPO Date: 2014-07-17
Fiscal Year End: December
Full Time Employees: 633
Back to stocks